View Financial HealthAccelerate Diagnostics 配当と自社株買い配当金 基準チェック /06Accelerate Diagnostics配当金を支払った記録がありません。主要情報n/a配当利回り-21,088,000.0%バイバック利回り総株主利回り-21,088,000.0%将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesAccelerate Diagnostics, Inc. announced delayed 10-Q filingAug 19Final DIP Financing Approved for Accelerate Diagnostics, Inc.Jun 06+ 1 more updateAccelerate Diagnostics, Inc. announced delayed 10-Q filingMay 17Accelerate Diagnostics, Inc.(OTCPK:AXDX.Q) dropped from NASDAQ Composite IndexMay 16Accelerate Diagnostics Receives Delisting Determination and Minimum Bid Price Non-Compliance Letter from NasdaqMay 13Motion for Joint Administration Approved for Accelerate Diagnostics, Inc.May 09+ 1 more updateMotion for Joint Administration Filed by Accelerate Diagnostics, Inc.May 08+ 1 more updateAccelerate Diagnostics, Inc. Announces Director Appointments, Effective from April 10, 2025Apr 16Accelerate Diagnostics Submits WAVE System and Gram-Negative Positive Blood Culture Menu to the FDA for 510(k) ClearanceMar 22Accelerate Diagnostics Receives Non-Compliance Letter Regarding Nasdaq MVLS RequirementJan 30Accelerate Diagnostics, Inc. Announces FDA Clearance of its Accelerate Arc™? SystemOct 01Accelerate Diagnostics, Inc. Announces Successful Completion of Its Wave Pre-Clinical TrialAug 09Accelerate Diagnostics, Inc. to Report Q1, 2024 Results on May 08, 2024May 03Accelerate Diagnostics, Inc. Receives Written Notice from the Listing Qualifications Staff of NasdaqMay 01Accelerate Diagnostics, Inc., Annual General Meeting, May 07, 2024Apr 13Accelerate Diagnostics, Inc. Receives Written Notice from the Listing Qualifications Staff of the Nasdaq Stock Market, LLCMar 06Accelerate Diagnostics, Inc. announced that it expects to receive $4.749996 million in funding from Jack W. Schuler Living TrustJan 25Accelerate Diagnostics, Inc. has completed a Composite Units Offering.Jan 21Accelerate Diagnostics Announces 1-For-10 Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement of $1.00 Per Share Required to Maintain Continued Listing on the Nasdaq Capital MarketJul 11First quarter 2023 earnings: EPS and revenues miss analyst expectations May 12Consensus EPS estimates fall by 15% Apr 25Market Participants Recognise Accelerate Diagnostics, Inc.'s (NASDAQ:AXDX) Revenues Pushing Shares 38% HigherApr 17Full year 2022 earnings: Revenues and EPS in line with analyst expectations Apr 06CEO, President & Director exercised options and sold US$73k worth of stock Mar 14Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Mar 06Insufficient new directors Mar 01Accelerate Diagnostics Receives A Deficiency Letter from Nasdaq Regarding Minimum Bid Price RequirementJan 12Consensus forecasts updated Nov 21Price target decreased to US$2.00 Nov 16Insider recently bought US$80k worth of stock Aug 31Accelerate Diagnostics spikes as Chief Technology Officer raises stake Aug 30Consensus revenue estimates increase by 10% Aug 22Need To Know: Analysts Are Much More Bullish On Accelerate Diagnostics, Inc. (NASDAQ:AXDX)Aug 20Second quarter 2022 earnings: EPS and revenues exceed analyst expectations Aug 16Accelerate Diagnostics jumps 14% after beating Q2 estimates Aug 15CEO, President & Director exercised options and sold US$26k worth of stock Jun 27Consensus forecasts updated May 23First quarter 2022 earnings: EPS exceeds analyst expectations May 17CEO, President & Director exercised options and sold US$82k worth of stock Apr 29Price target decreased to US$5.00 Apr 27Need To Know: The Consensus Just Cut Its Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Estimates For 2022Mar 15Consensus revenue estimates fall by 14% Mar 15Full year 2021 earnings: EPS exceeds analyst expectations Mar 09Insider recently bought US$66k worth of stock Feb 03Independent Director recently bought US$524k worth of stock Jan 21Independent Director recently bought US$196k worth of stock Jan 16Independent Director recently bought US$277k worth of stock Jan 07Accelerate Diagnostics And T2 Biosystems: Financial Woes Set To Continue In 2022 Jan 04Independent Director recently bought US$369k worth of stock Dec 24Independent Director recently bought US$248k worth of stock Nov 30Independent Director recently bought US$606k worth of stock Nov 26Third quarter 2021 earnings released: US$0.15 loss per share (vs US$0.33 loss in 3Q 2020) Nov 10Third quarter 2021 earnings released: US$0.15 loss per share (vs US$0.33 loss in 3Q 2020) Nov 10Independent Director recently bought US$150k worth of stock Sep 28Price target decreased to US$11.00 Sep 24Accelerate Diagnostics: An Investment Assessment Sep 07Second quarter 2021 earnings released: US$0.35 loss per share (vs US$0.35 loss in 2Q 2020) Aug 12Consensus forecasts updated Aug 07CEO, President & Director exercised options and sold US$186k worth of stock Jun 25Key Executive exercised options and sold US$56k worth of stock May 16Price target decreased to US$11.00 May 11First quarter 2021 earnings released: US$0.41 loss per share (vs US$0.39 loss in 1Q 2020) May 09Analysts lower revenue estimates to US$16.5m Mar 02Earnings beat expectations, revenue disappoints Feb 25Full year 2020 earnings released: US$1.40 loss per share (vs US$1.55 loss in FY 2019) Feb 25Should You Take Comfort From Insider Transactions At Accelerate Diagnostics, Inc. (NASDAQ:AXDX)?Feb 20Key Executive exercised options and sold US$701k worth of stock Jan 29New 90-day high: US$12.96 Jan 26Price target lowered to US$12.33 Jan 16Reflecting on Accelerate Diagnostics' (NASDAQ:AXDX) Share Price Returns Over The Last Three YearsDec 29New 90-day low: US$7.04 Dec 10Price target lowered to US$14.33 Dec 06Key Executive exercised options and sold US$256k worth of stock Nov 13New 90-day low: US$8.87 Nov 10Revenue beats expectations Nov 08Third quarter 2020 earnings released: US$0.33 loss per share Nov 08New 90-day low: US$9.88 Oct 22Accelerate Diagnostics, Inc. Announces New FDA Clearance for Accelerate PhenoTest® ImprovementsSep 17決済の安定と成長配当データの取得安定した配当: AXDX.Qの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: AXDX.Qの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場Accelerate Diagnostics 配当利回り対市場AXDX.Q 配当利回りは市場と比べてどうか?セグメント配当利回り会社 (AXDX.Q)n/a市場下位25% (US)1.4%市場トップ25% (US)4.2%業界平均 (Medical Equipment)2.2%アナリスト予想 (AXDX.Q) (最長3年)n/a注目すべき配当: AXDX.Qは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: AXDX.Qは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: AXDX.Qの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: AXDX.Qが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YUS 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日(UTC時間)企業分析2025/08/22 11:32終値2025/08/20 00:00収益2024/12/31年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM(Trailing Twelve Month)またはLTM(Last Twelve Month)データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Accelerate Diagnostics, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。4 アナリスト機関Sean LavinBTIGAlexander NowakCraig-Hallum Capital Group LLCTycho PetersonJ.P. Morgan1 その他のアナリストを表示
Accelerate Diagnostics Receives Delisting Determination and Minimum Bid Price Non-Compliance Letter from NasdaqMay 13
Accelerate Diagnostics Submits WAVE System and Gram-Negative Positive Blood Culture Menu to the FDA for 510(k) ClearanceMar 22
Accelerate Diagnostics, Inc. Receives Written Notice from the Listing Qualifications Staff of NasdaqMay 01
Accelerate Diagnostics, Inc. Receives Written Notice from the Listing Qualifications Staff of the Nasdaq Stock Market, LLCMar 06
Accelerate Diagnostics, Inc. announced that it expects to receive $4.749996 million in funding from Jack W. Schuler Living TrustJan 25
Accelerate Diagnostics Announces 1-For-10 Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement of $1.00 Per Share Required to Maintain Continued Listing on the Nasdaq Capital MarketJul 11
Market Participants Recognise Accelerate Diagnostics, Inc.'s (NASDAQ:AXDX) Revenues Pushing Shares 38% HigherApr 17
Accelerate Diagnostics Receives A Deficiency Letter from Nasdaq Regarding Minimum Bid Price RequirementJan 12
Need To Know: The Consensus Just Cut Its Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Estimates For 2022Mar 15
Should You Take Comfort From Insider Transactions At Accelerate Diagnostics, Inc. (NASDAQ:AXDX)?Feb 20
Reflecting on Accelerate Diagnostics' (NASDAQ:AXDX) Share Price Returns Over The Last Three YearsDec 29
Accelerate Diagnostics, Inc. Announces New FDA Clearance for Accelerate PhenoTest® ImprovementsSep 17